Treatment of Human Mesenchymal Stem Cells with Angiotensin Receptor Blocker Improved Efficiency of Cardiomyogenic Transdifferentiation and Improved Cardiac Function via Angiogenesis
Treatment of Human Mesenchymal Stem Cells with Angiotensin Receptor Blocker Improved Efficiency of Cardiomyogenic Transdifferentiation and Improved Cardiac Function via Angiogenesis
复制标题
DOI：
10.1002/stem.691
复制
发表时间：
2011-09-01
期刊：
影响因子：
5.2
通讯作者：
Umezawa, Akihiro
中科院分区：
文献类型：
--
作者：
Numasawa, Yohei;Kimura, Takehiro;Umezawa, Akihiro
为了提高骨髓间充质干细胞(MSC)移植的适度疗效，研究了血管紧张素受体阻滞剂(ARB)对人MSCs的治疗作用。MSCs在心肌诱导前分别加入或不加入含3mU·mol/L ARB的培养液。体外诱导后，用抗心肌肌钙蛋白-I抗体免疫细胞化学方法计算心肌细胞的转分化效率(CTE)。在裸鼠慢性心肌梗死模型中，分别注射经坎地沙坦处理的MSCs(A-BM；n=18)或不加坎地沙坦的MSCs(BM；n=25)，每组存活2周。超声心动图测定的左心功能与免疫组织化学方法测定的体内心肌源性转分化进行比较。ARBS可显著增加体外CTE(10.1+/-0.8n=12 vs.4.6+/-0.3%n=25，p
To improve the modest efficacy of mesenchymal stem cell (MSC) transplantation, the treatment of human MSCs with angiotensin receptor blockers (ARBs) was investigated. MSCs were cultured with or without the medium containing 3 mu mol/l of ARBs before cardiomyogenic induction. After cardiomyogenic induction in vitro, cardiomyogenic transdifferentiation efficiency (CTE) was calculated by immunocytochemistry using anticardiac troponin-I antibody. In the nude rat chronic myocardial infarction model, we injected MSCs pretreated with candesartan (A-BM; n = 18) or injected MSCs without pretreatment of candesartan (BM; n = 25), each having survived for 2 weeks. The left ventricular function, as measured by echocardiogram, was compared with cardiomyogenic transdifferentiation in vivo, as determined by immunohistochemistry. Pretreatment with ARBs significantly increased the CTE in vitro (10.1 +/- 0.8 n = 12 vs. 4.6 +/- 0.3% n = 25, p